Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carl Crysler

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Bioorganic & Medicinal Chemistry Letters|May 3, 2005
Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acidsKristi Leonard, Wenxi Pan, Beth Anaclerio, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2011
The discovery of novel cyclohexylamide CCR2 antagonistsJames C Lanter, Thomas P Markotan, Xuqing Zhang, et al.
The Journal of Biological Chemistry|November 6, 2007
Structural basis for elastolytic substrate specificity in rodent alpha-chymasesJukka Kervinen, Marta Abad, Carl Crysler, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2008
Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptorMichael P Winters, Carl Crysler, Nalin Subasinghe, et al.
Bioorganic & Medicinal Chemistry Letters|April 19, 2008
Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motifKevin D Kreutter, Tianbao Lu, Lily Lee, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitorsMark J Wall, Jinsheng Chen, Sanath Meegalla, et al.
Molecular Cancer Therapeutics|November 6, 2009
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaCarl L Manthey, Dana L Johnson, Carl R Illig, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Bioorganic & Medicinal Chemistry Letters|May 3, 2005
Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acidsKristi Leonard, Wenxi Pan, Beth Anaclerio, et al.
Bioorganic & Medicinal Chemistry Letters|November 9, 2011
The discovery of novel cyclohexylamide CCR2 antagonistsJames C Lanter, Thomas P Markotan, Xuqing Zhang, et al.
The Journal of Biological Chemistry|November 6, 2007
Structural basis for elastolytic substrate specificity in rodent alpha-chymasesJukka Kervinen, Marta Abad, Carl Crysler, et al.
Bioorganic & Medicinal Chemistry Letters|March 1, 2008
Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptorMichael P Winters, Carl Crysler, Nalin Subasinghe, et al.
Bioorganic & Medicinal Chemistry Letters|April 19, 2008
Orally efficacious thrombin inhibitors with cyanofluorophenylacetamide as the P2 motifKevin D Kreutter, Tianbao Lu, Lily Lee, et al.
Bioorganic & Medicinal Chemistry Letters|February 22, 2008
Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitorsMark J Wall, Jinsheng Chen, Sanath Meegalla, et al.
Molecular Cancer Therapeutics|November 6, 2009
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaCarl L Manthey, Dana L Johnson, Carl R Illig, et al.
Pageof 2